Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs
Philip Kranz, Natalie McGauran, Can Ünal, Thomas Kaiser · 2024
Read Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs by Philip Kranz, Natalie McGauran, Can Ünal, Thomas Kaiser (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11703625.txt.
Description
Drugs for rare diseases win approval on thin evidence, and Germany then asks whether they truly add benefit over existing care. Philip Kranz, Natalie McGauran, Can Unal, and Thomas Kaiser review a decade of those German assessments. They cover eighty-nine orphan drugs judged across one hundred seventy-five separate questions.
In the fast first-pass assessments, the added benefit could not be quantified in nearly eighty percent of questions. In full assessments, over half the questions ended with no proof of added benefit, mostly for lack of head-to-head data. Most drugs targeted diseases that already had treatments, and cancer loomed large despite being a small share of rare diseases. The authors call for incentives steering research toward true gaps and toward comparative trials.
Catalog record
| CREATOR | Philip Kranz, Natalie McGauran, Can Ünal, Thomas Kaiser |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |